دورية أكاديمية
Tailored Toxicity-Driven Administration of Vismodegib in Patients With Multiple or Locally Advanced Basal Cell Carcinoma: A Pilot Analysis.
| العنوان: | Tailored Toxicity-Driven Administration of Vismodegib in Patients With Multiple or Locally Advanced Basal Cell Carcinoma: A Pilot Analysis. |
|---|---|
| المؤلفون: | Tronconi MC; Medical Oncology and Hematology Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center, IRCCS, Rozzano, Italy., Solferino A; Pharmacist Oncology and Hematology Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center, IRCCS, Rozzano, Italy., Giordano L; Biostatistics Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center, IRCCS, Rozzano, Italy., Borroni R; Dermatology Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center, IRCCS, Rozzano, Italy.; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy., Mancini L; Dermatology Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center, IRCCS, Rozzano, Italy., Santoro A; Medical Oncology and Hematology Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center, IRCCS, Rozzano, Italy.; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy. |
| المصدر: | Frontiers in oncology [Front Oncol] 2020 Nov 13; Vol. 10, pp. 563404. Date of Electronic Publication: 2020 Nov 13 (Print Publication: 2020). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مستخلص: | In this pilot study, we describe our experience with vismodegib in the treatment of basal cell carcinoma (BCC) and evaluate the feasibility of a tailored toxicity-driven administration of vismodegib in patients with multiple or locally advanced BCC. We retrospectively analyzed the clinical charts of 17 consecutive patients with BCC who were treated with vismodegib. Therapy was started at the usual dosage of 150 mg per day per person, continuously; a rescheduled dosage of 150 mg per day for 4 weeks with a subsequent stop of 2 weeks was allowed during the treatment according to the standard practice of our institution. During treatment, 14 patients with responsive disease presented an adverse event (100% cramps and 20% dysgeusia), therefore, requiring a change in the treatment plan. Overall, in eight out of 17 patients (47% of the overall population), it was possible to re-schedule the treatment by postponing therapy for 2 weeks every 4 weeks. These patients were all still alive at the time of the present analysis and were showing complete response. Adverse events resolved during the first interruption of therapy. The intermittent vismodegib schedule assessed in this pilot series could be beneficial in improving duration of treatment, allowing to maintain a long-term treatment response, even in an elderly and fragile population. Based on these preliminary findings, dedicated studies may be planned to further evaluate an intermittent schedule of vismodegib administration. (Copyright © 2020 Tronconi, Solferino, Giordano, Borroni, Mancini and Santoro.) |
| References: | N Engl J Med. 2012 Jun 7;366(23):2171-9. (PMID: 22670903) J Am Acad Dermatol. 2019 Feb;80(2):303-317. (PMID: 29782900) J Am Acad Dermatol. 2015 Jun;72(6):1021-6.e8. (PMID: 25981002) Drug Saf. 2019 Feb;42(2):263-279. (PMID: 30649745) Dermatol Ther (Heidelb). 2019 Sep;9(3):505-510. (PMID: 31165365) Future Oncol. 2015;11(9):1429-35. (PMID: 25952787) Int J Dermatol. 2020 May;59(5):627-632. (PMID: 32034775) Target Oncol. 2019 Jun;14(3):253-267. (PMID: 31243642) Curr Treat Options Oncol. 2019 Feb 11;20(2):13. (PMID: 30741348) Target Oncol. 2018 Apr;13(2):253-256. (PMID: 29235062) J Eur Acad Dermatol Venereol. 2020 Sep;34(9):1944-1956. (PMID: 31990414) Actas Dermosifiliogr. 2018 Nov;109(9):813-820. (PMID: 30055751) Dermatol Ther. 2018 Jan;31(1):. (PMID: 28976624) Lancet Oncol. 2017 Mar;18(3):404-412. (PMID: 28188086) Lancet Oncol. 2015 Jun;16(6):729-36. (PMID: 25981813) Curr Treat Options Oncol. 2019 Nov 26;20(11):84. (PMID: 31773379) Eur J Dermatol. 2018 Dec 1;28(6):775-783. (PMID: 30698147) Drugs. 2018 Jul;78(11):1145-1156. (PMID: 30030732) Eur J Cancer. 2017 Nov;86:334-348. (PMID: 29073584) |
| فهرسة مساهمة: | Keywords: basal cell carcinoma; schedule; tailored treatment; toxicity; vismodegib |
| تواريخ الأحداث: | Date Created: 20201207 Latest Revision: 20201208 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC7691528 |
| DOI: | 10.3389/fonc.2020.563404 |
| PMID: | 33282729 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!